« Back

Tom King is President and a member of the Board of Directors at Satsuma, bringing more than 40 years of leadership experience across the biopharmaceutical industry, spanning emerging development-stage companies to publicly traded commercial organizations. Throughout his career, he has successfully built, operated, and led the strategic growth and sale of multiple specialty pharmaceutical companies with commercial products. Most recently, Tom served as Interim Executive Chair of Achieve Life Sciences, Inc. (Nasdaq: ACHV) from August 2024 to June 2025 and was a member of the company’s Board of Directors from 2023 to 2026. He previously served on the Board of Directors of VIVUS, Inc. (Nasdaq: VVUS) from 2017 to 2020, including periods as Interim Chief Executive Officer and Interim President. From 2003 to 2016, Tom was President, Chief Executive Officer, and a member of the Board of Directors of Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA). Alexza focused on the development and commercialization of rapid-onset inhaled therapies for central nervous system conditions using its proprietary Staccato® drug delivery platform, including the U.S. and international approvals of Adasuve® (Staccato loxapine). Under Tom’s leadership, Alexza advanced from a development-stage company to a commercial organization and was ultimately acquired by Grupo Ferrer in 2016. Tom also held several senior leadership roles at Anesta Corporation (Nasdaq: NSTA), including President and Chief Operating Officer and later President and Chief Executive Officer. Anesta specialized in pain management and advanced drug delivery technologies, including innovative transmucosal therapeutic systems that resulted in multiple U.S. and international product approvals. The company was acquired by Cephalon, Inc. in 2000. Tom earned a B.A. in Chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.